Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude appoints Mark Carlson as CMO

This article was originally published in The Gray Sheet

Executive Summary

Effective Nov. 13, Mark Carlson, MD, becomes chief medical officer and senior VP-clinical affairs for St. Jude Medical's cardiac rhythm management division. Carlson recently chaired the Heart Rhythm Society's task force to develop recommendations for post-market surveillance of implantable heart devices, issued Sept. 28 (1"The Gray Sheet" Oct. 2, 2006, p. 3). Carlson will coordinate clinical studies on new and existing heart devices and therapies and will serve as a liaison to the medical community...

You may also be interested in...

Heart Rhythm Society Finalizes Recommendations, Urges Postmarket Reform

The Heart Rhythm Society's final recommendations for industry, FDA and physicians on handling malfunctions of implantable heart devices, issued Sept. 28, "are only the beginning of what needs to happen," said HRS President Dwight Reynolds, MD

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts